Table of Contents
<< Previous Issue | Dec 2019 (Vol: 2019, Issue: 12) | Next Issue >> |
- Section: Licensing
-
Jazz Pharmaceuticals Licenses PharmaMar’s Lung Cancer Drug Lurbinectedin
-
Roche Licenses Sarepta’s DMD Therapy for US$2.88 B
- Section: Mergers & Acquisitions
-
Astellas Pushes Further into Gene Therapy Field with US$3 B Audentes Buy
-
Sanofi Ups Immuno-oncology Investment with US$2.5 B Synthorx Buy
-
Merck Validates BTK Inhibitors with US$2.7 B ArQule Buy
- Section: Opinion & Analysis
-
Deal Trends in Gene Therapy
- Section: Research & Development
-
Neurocrine Signs US$1.7 B Epilepsy Pact with Xenon
-
Takeda Buys into Viral Immunology with US$1 B Turnstone Deal